In yesterday’s Wall Street session, Seres Therapeutics Inc. (NASDAQ:MCRB) shares traded at $4.69, up 6.11% from the previous session.
As of this writing, 7 analysts cover Seres Therapeutics Inc. (NASDAQ:MCRB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $4.00, we find $11.00. Given the previous closing price of $4.42, this indicates a potential upside of 148.87 percent. MCRB stock price is now -5.85% away from the 50-day moving average and -18.09% away from the 200-day moving average. The market capitalization of the company currently stands at $565.29M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 1 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $10.17 as their price target over the next twelve months.
In other news, Ege David S., insider sold 7,038 shares of the company’s stock on Apr 28. The stock was sold for $36,527 at an average price of $5.19. Upon completion of the transaction, the insider now directly owns 59,696 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 31, Ege David S. sold 5,012 shares of the business’s stock. A total of $39,745 was realized by selling the stock at an average price of $7.93. This leaves the insider owning 46,734 shares of the company worth $0.22 million. Insiders disposed of 12,050 shares of company stock worth roughly $56514.50000000001 over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MCRB stock. A new stake in Seres Therapeutics Inc. shares was purchased by AVORO CAPITAL ADVISORS LLC during the first quarter worth $6,074,000. HANDELSBANKEN FONDER AB invested $3,752,000 in shares of MCRB during the first quarter. In the first quarter, SIMPLIFY ASSET MANAGEMENT INC. acquired a new stake in Seres Therapeutics Inc. valued at approximately $2,582,000. AE WEALTH MANAGEMENT LLC acquired a new stake in MCRB for approximately $446,000. MACH-1 FINANCIAL GROUP, LLC purchased a new stake in MCRB valued at around $445,000 in the second quarter.
Friday morning saw Seres Therapeutics Inc. (NASDAQ: MCRB) opened at $4.5000. During the past 12 months, Seres Therapeutics Inc. has had a low of $3.91 and a high of $9.49. The fifty day moving average price for MCRB is $4.9736 and a two-hundred day moving average price translates $5.7144 for the stock.
The latest earnings results from Seres Therapeutics Inc. (NASDAQ: MCRB) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.57, missing analysts’ expectations of -$0.55 by -0.02. This compares to -$0.61 EPS in the same period last year. The company reported revenue of $-0.52 million for the quarter, compared to $1.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -134.96 percent. For the current quarter, analysts expect MCRB to generate $125.7M in revenue.
